🇺🇸 FDA
Pipeline program

REN001

REN001-202

Phase 3 small_molecule terminated

Quick answer

REN001 for Primary Mitochondrial Myopathy is a Phase 3 program (small_molecule) at OnKure Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
OnKure Therapeutics
Indication
Primary Mitochondrial Myopathy
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials